4 research outputs found
Metagenomic pipeline for identifying co-infections among distinct SARS-CoV-2 variants of concern: Study cases from Alpha to Omicron
Concomitant infection or co-infection with distinct SARS-CoV-2 genotypes have been reported as part of
the epidemiological surveillance of the COVID-19 pandemic. In the context of the spread of more
transmissible variants during 2021, co-infections are not only important due to the possible changes in
the clinical outcome, but also the chance to generate new genotypes by recombination. However, a few
approaches have developed bioinformatic pipelines to identify co-infections.
Here we present a metagenomic pipeline based on the inference of multiple fragments similar to
amplicon sequence variant (ASV-like) from sequencing data and a custom SARS-CoV-2 database to
identify the concomitant presence of divergent SARS-CoV-2 genomes, i.e., variants of concern (VOCs).
This approach was compared to another strategy based on whole-genome (metagenome) assembly.
Using single or pairs of sequencing data of COVID-19 cases with distinct SARS-CoV-2 VOCs, each
approach was used to predict the VOC classes (Alpha, Beta, Gamma, Delta, Omicron or non-VOC and their
combinations). The performance of each pipeline was assessed using the ground-truth or expected VOC
classes. Subsequently, the ASV-like pipeline was used to analyze 1021 cases of COVID-19 from Costa
Rica to investigate the possible occurrence of co-infections.
After the implementation of the two approaches, an accuracy of 96.2% was revealed for the ASV-like
inference approach, which contrasts with the misclassification found (accuracy 46.2%) for the wholegenome assembly strategy. The custom SARS-CoV-2 database used for the ASV-like analysis can be
updated according to the appearance of new VOCs to track co-infections with eventual new genotypes. In
addition, the application of the ASV-like approach to all the 1021 sequenced samples from Costa Rica in
the period October 12th - December 21th 2021 found that none corresponded to co-infections with VOCs.
In conclusion, we developed a metagenomic pipeline based on ASV-like inference for the identification of
co-infection with distinct SARS-CoV-2 VOCs, in which an outstanding accuracy was achieved. Due to the
epidemiological, clinical, and molecular relevance of the concomitant infection with distinct genotypes,
this work represents another piece in the process of the surveillance of the COVID-19 pandemic in Costa
Rica and worldwide.Universidad de Costa Rica/[803-C0-196]/UCR/Costa RicaUCR::Vicerrectoría de Docencia::Salud::Facultad de Microbiologí
Clinical profiles at the time of diagnosis of COVID-19 in Costa Rica during the pre-vaccination period using a machine learning approach
Background: The clinical manifestations of COVID-19 disease, caused by the SARS-CoV-2
virus, define a large spectrum of symptoms that are mainly dependent on the human host
conditions. In Costa Rica, almost 319 000 cases have been reported during the first third of
2021, contrasting to the 590 000 fully vaccinated people. In the pre-vaccination period (the
year 2020), this country accumulated 169 321 cases and 2185 deaths.
Methods: To describe the clinical presentations at the time of diagnosis of COVID-19 in
Costa Rica during the pre-vaccination period, we implemented a symptom-based clustering
using machine learning to identify clusters or clinical profiles among 18 974 records of
positive cases. Profiles were compared based on symptoms, risk factors, viral load, and
genomic features of the SARS-CoV-2 sequence.
Results: A total of seven COVID-19 clinical profiles were identified, which were characterized
by a specific composition of symptoms. In the comparison between clusters, a lower viral
load was found for the asymptomatic group, while the risk factors and the SARS-CoV-2
genomic features were distributed among all the clusters. No other distribution patterns
were found for age, sex, vital status, and hospitalization.
Conclusion: During the pre-vaccination time in Costa Rica, the clinical manifestations at the
time of diagnosis of COVID-19 were described in seven profiles. The host co-morbidities and
the SARS-CoV-2 genotypes are not specific of a particular profile, rather they are present in
all the groups, including asymptomatic cases. In further analyses, these results will be
compared against the profiles of cases during the vaccination period.UCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias de la Salud::Centro de Investigación en Enfermedades Tropicales (CIET)UCR::Vicerrectoría de Docencia::Salud::Facultad de Medicina::Escuela de Medicin
SARS-CoV-2 genomic surveillance in Costa Rica: Evidence of a divergent population and an increased detection of a spike T1117I mutation
Genome sequencing is a key strategy in the surveillance of SARS-CoV-2, the virus responsible for the COVID-19 pandemic. Latin America is the hardest-hit region of the world, accumulating almost 20% of COVID-19 cases worldwide. In Costa Rica, from the first detected case on March 6th to December 31st almost 170,000 cases have been reported. We analyzed the genomic variability during the SARS-CoV-2 pandemic in Costa Rica using 185 sequences, 52 from the first months of the pandemic, and 133 from the current wave. Three GISAID clades (G, GH, and GR) and three PANGOLIN lineages (B.1, B.1.1, and B.1.291) were predominant, suggesting multiple re-introductions from other regions. The whole-genome variant calling analysis identified a total of 283 distinct nucleotide variants, following a power-law distribution with 190 single nucleotide mutations in a single sequence, and only 16 mutations were found in >5% sequences. These mutations were distributed through the whole genome. The prevalence of worldwide-found variant D614G in the Spike (98.9% in Costa Rica), ORF8 L84S (1.1%) is similar to what is found elsewhere. Interestingly, the frequency of mutation T1117I in the Spike has increased during the current pandemic wave beginning in May 2020 in Costa Rica, reaching 29.2% detection in the full genome analyses in November 2020. This variant has been observed in less than 1% of the GISAID reported sequences worldwide in 2020. Structural modeling of the Spike protein with the T1117I mutation suggests a potential effect on the viral oligomerization needed for cell infection, but no differences with other genomes on transmissibility, severity nor vaccine effectiveness are predicted. In conclusion, genome analyses of the SARS-CoV-2 sequences over the course of the COVID-19 pandemic in Costa Rica suggest the introduction of lineages from other countries and the detection of mutations in line with other studies, but pointing out the local increase in the detection of Spike-T1117I variant. The genomic features of this virus need to be monitored and studied in further analyses as part of the surveillance program during the pandemic.Instituto Costarricense de Investigación y Enseñanza en Nutrición y Salud/[]/INCIENSA/Costa RicaUniversidad de Costa Rica/[803-C0-196]/UCR/Costa RicaCOINGESA-CR Consorcio Interinstitucional de Estudios Genómicos del SARS-CoV-2 Costa RicaUCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias de la Salud::Centro de Investigación en Enfermedades Tropicales (CIET)UCR::Vicerrectoría de Docencia::Salud::Facultad de Microbiologí
Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH survey
Background: Scant information is available about how transplant centers are managing their use of quantitative molecular testing (QNAT) assays for active cytomegalovirus (CMV) infection monitoring in solid organ transplant (SOT) recipients. The current study was aimed at gathering information on current practices in the management of CMV infection across European centers in the era of molecular testing assays. Methods: A questionnaire-based cross-sectional survey study was conducted by the European Study Group of Infections in Immunocompromised Hosts (ESGICH) of the Society of Clinical Microbiology and Infectious Diseases (ESCMID). The invitation and a weekly reminder with a personal link to an Internet service provider (https://es.surveymonkey.com/) was sent to transplant physicians, transplant infectious diseases specialists, and clinical virologists working at 340 European transplant centers. Results: Of the 1181 specialists surveyed, a total of 173 responded (14.8%): 73 transplant physicians, 57 transplant infectious diseases specialists, and 43 virologists from 173 institutions located at 23 different countries. The majority of centers used QNAT assays for active CMV infection monitoring. Most centers preferred commercially available real-time polymerase chain reaction (RT-PCR) assays over laboratory-developed procedures for quantifying CMV DNA load in whole blood or plasma. Use of a wide variety of DNA extraction platforms and RT-PCR assays was reported. All programs used antiviral prophylaxis, preemptive therapy, or both, according to current guidelines. However, the centers used different criteria for starting preemptive antiviral treatment, for monitoring systemic CMV DNA load, and for requesting genotypic assays to detect emerging CMV-resistant variants. Conclusions: Significant variation in CMV infection management in SOT recipients still remains across European centers in the era of molecular testing. International multicenter studies are required to achieve commutability of CMV testing and antiviral management procedures